Acomplia (Rimonabant) Diet Pill
What is Acomplia
A diet pill called Acomplia (Rimonabant) could help
you lose as much as 10 percent of your body weight if
you take it over a year's time according to new research.
After two years of treatment, patients in the study
maintained a 16-pound weight loss. More than a third
of patients taking the drug lost 10% of their body weight.
Acomplia diet pill makes an effect directly
on the Endocannabinoid system which operates appetite
and energy outflow. It exclusively wedges CB-1 receptors
of the Endocannabinoid system and thus formulates
a fine equilibrium which in turn represses appetite
and craving to eat. But this does not entails that
peerless efficacy of this rimonabant is explicitly
restricted to obese population only. Acomplia diet
drug results promising outcomes while smoking cessation
as well. Its dual healing property is the key factor
which lends a supreme to this terrific diet drug among
all available. Thus it is a reliable means just not
for weight loss but to relinquish smoking in addition.
Rimonabant is a popular prescription weight loss
drug that is currently available in 18 countries (under
the name Acomplia - from Sanofi-Aventis).
- Rimonabant 20 mg daily vs. placebo was associated
with statistically and clinically significant weight
loss.
- Rimonabant 5 mg daily vs. placebo was associated
with statistically significant but clinically insignificant
weight loss.
Permission
The European Commission gave permission for the sale
of Rimonabant Acomplia prescription
weight loss drugs to treat obesity and weight loss
with a BMI ( body mass index) of 30 or above as well
as for smoking cessation treatments.
"The approval of Rimonabant Acomplia
in the European Union is important news for obese
and overweight patients with additional cardiometabolic
risk factors such as type 2 diabetes or dyslipidaemia
who will now have access to an innovative treatment
option," said Sanofi CEO Jean-François
Dehecq.
Sanofi said that after the launch of Acomplia
(Rimonabant) in the United Kingdom, it will
be launched during the second half of 2006 in Denmark,
Ireland, Germany, Finland and Norway as well.
Sanofi provided no updates on the status of the approval
process at the U.S. Food and Drug Administration.
"Now we shall take care with this product, we
shall work hard in conjunction with the medical community
in order to insure that is will be prescribed to patients
who stand to benefit the most from it," Dehecq
said.
Sanofi CEO Jean-François Dehecq Dehecq said
those likely to gain the most benefit from Rimonabant
Acomplia are "obese patients with
serious metabolic and cardiometabolic risks."
A 20-mg per day version has been authorized for all
25 EU member states, with the first launch set for
the UK in July.
Acomplia, also known as Rimonabant Acomplia,
is used to treat weight loss and obesity diseases
for patients at risk of heart complications or type
II diabetes
Update Jun 13 2007:
An FDA advisory panel of outside experts unanimously
recommended that the regulatory agency not approve
the novel weight-loss drug for sale in the United
States.
|
